Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

HIV Drug ResistanceHIV Drug Resistance
          
Rollover images to visit our other forums!
  
  • Email Email
  • Glossary Glossary


Triomune
Nov 25, 2001

Triomune is the world's first fixed-dose formulation containing a combination of 2 widely used nucleoside reverse transcriptase inhibitors (stavudine and lamivudine), with 1 potent non-nucleoside reverse transcriptase inhibitor (nevirapine). Triomune can be taken twice daily, irrespective of food.

Is there anything like this in US drug market?

Response from Dr. Pavia

I am not familiar with the brand name of the combination you mention. It is an attractive combination since the three drugs are often prescribed together in the US. However, the combination is not produced in the US or Europe.

It must be produced by a generic manufacterer overseas. Stavudine, lamivudine and nevirapine are each under patent to different pharmaceutical companies, and could only be produced in the US or any other country that follows the GATT patent laws, is if there was an agreement between the companies to co-market.

ATP


Previous
Shall I medicate?
Next
re kaletra without food

  
  • Email Email
  • Glossary Glossary


 
Advertisement




Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement